The initial recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) for the scheduling of Naproxen were finalized effective June 11, 2009 to read as follows:
- Naproxen sodium 220 mg tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6,600 mg) – Schedule III
- Naproxen sodium 220 mg tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6,600 mg) – Schedule II
The National Drug Schedules will be revised accordingly.
Originally published in the June 16, 2009, issue of The Link
